Kathryn Shimamoto

Kathryn Shimamoto

Auto-generated profile, based on publicly available information

Kathryn Shimamoto

University of Chicago 1 Section of Hematology/Oncology, Department of Medicine Chicago, Illinois

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
CSCaner Saygin
Caner Saygin
GGGiorgia Giordano
Giorgia Giordano
KSKathryn Shimamoto
Kathryn Shimamoto
BEBart Eisfelder
Bart Eisfelder
ATAnika Thomas-Toth
Anika Thomas-Toth
WSWendy Stock
Wendy Stock
Purpose: Relapsed T-acute lymphoblastic leukemia (T-ALL) has limited treatment options. We investigated mechanisms of resistance to BH3 mimetics in T-ALL to develop rational combination strategies. We also looked at the preclinical efficacy of NWP-0476, a novel BCL-2/BCL-xL inhibitor, as single agent and combination therapy in T-ALL. Experimental Design: We used BH3 profiling as a predictive tool for BH3 mimetic response in T-ALL. Using isogenic control, venetoclax-resistant (ven-R) and NWP-0476-resistant (NWP-R) cells, phosphokinase array was performed to identify differentially regulated signaling pathways. Results: Typical T-ALL cells had increased dependence on BCL-xL, whereas early T-precursor (ETP)-ALL cells had higher BCL-2 dependence for survival. BCL-2/BCL-xL dual inhibitors were effective against both subtypes of T-lineage ALL. A 71-protein human phosphokinase array showed increased LCK activity in ven-R cells, and increased ACK1 activity in ven-R and NWP-R cells. We hypothesized that pre-TCR and ACK1 signaling pathways are drivers of resistance to BCL-2 and BCL-xL inhibition, respectively. First, we silenced LCK gene in T-ALL cell lines, which resulted in increased sensitivity to BCL-2 inhibition. Mechanistically, LCK activated NF-κB pathway and the expression of BCL-xL. Silencing ACK1 gene resulted in increased sensitivity to both BCL-2 and BCL-xL inhibitors. ACK1 signaling upregulated AKT pathway, which inhibited the pro-apoptotic function of BAD. In a T-ALL patient-derived xenograft model, combination of NWP-0476 and dasatinib demonstrated synergy without major organ toxicity. Conclusions: LCK and ACK1 signaling pathways are critical regulators of BH3 mimetic resistance in T-ALL. Combination of BH3 mimetics with tyrosine kinase inhibitors might be effective against relapsed T-ALL.

16 July 2025 in Leukemia
Verified
Journal Article
Open access
PDF file
JCJennifer H. Cooperrider
Jennifer H. Cooperrider
DKDiren Arda Karaoglu
Diren Arda Karaoglu
TKTadeusz Kubicki
Tadeusz Kubicki
CJCan Rui Jiang
Can Rui Jiang
EPElla Postich
Ella Postich
CSCaner Saygin
Caner Saygin

4 April 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
KSKathryn Shimamoto
Kathryn Shimamoto
DKDiren Arda Karaoğlu
Diren Arda Karaoğlu
OAOlivia Arnold
Olivia Arnold
ADArjun Dhar
Arjun Dhar
ZCZachary Chan
Zachary Chan
CSCaner Saygin
Caner Saygin
T-lineage acute lymphoblastic leukemia (T-ALL) lacks effective targeted therapies, with poor outcomes in relapsed/refractory (R/R) disease. HOXAhigh T-ALL is biologically aggressive and often resistant to standard therapy. Menin inhibitors, recently approved for KMT2A-rearranged leukemias, may be effective in T-ALL, but biomarkers of response remain undefined. This study aims to evaluate the efficacy of menin inhibition in T-ALL and identify molecular predictors of sensitivity. We tested menin inhibitors (ziftomenib, revumenib, and VTP50469) in 14 primary T-ALL samples and 8 cell lines, representing HOXAhigh and HOXAlow genotypes. In vitro sensitivity assays, xenograft mouse models, transcriptomics, proteomics, and phosphoproteomics were used to characterize drug response. MEF2C modulation experiments and combination studies with cyclin-dependent kinase (CDK) 1/2 and ERK1/2 inhibitors were performed in vitro and in vivo. Menin inhibitors suppressed leukemic growth in a subset of HOXAhigh and HOXAlow primary human T-ALL samples. Similarly, ziftomenib was effective in reducing tumor burden in xenografts without major toxicity. Upon treatment, we observed downregulation of canonical menin targets (HOXA, MEIS1, and MEF2C) and upregulation of T-cell differentiation programs. Phosphoproteomic studies identified MEF2C S222 phosphorylation—mediated by CDK1/2 and ERK1/2—as a predictor of ziftomenib sensitivity in T-ALL. MEF2C overexpression promoted proliferation and ziftomenib resistance, whereas its knockdown impaired growth. Ziftomenib synergized with CDK1/2 and ERK1/2 inhibitors in vitro and improved survival in xenografted mice. In conclusion, a subset of T-ALL, defined by high p-MEF2C S222, is sensitive to menin inhibition. Combining ziftomenib with CDK or ERK inhibition offers synergistic efficacy, supporting biomarker-driven clinical trials of this strategy in R/R T-ALL.


4 August 2026
Verified
Other
Open access
KSKathryn Shimamoto
Kathryn Shimamoto
DKDiren Arda Karaoğlu
Diren Arda Karaoğlu
OAOlivia Arnold
Olivia Arnold
ADArjun Dhar
Arjun Dhar
ZCZachary Chan
Zachary Chan
CSCaner Saygin
Caner Saygin
Gene network maps showing fold-changes in the genes involved in down-regulated (A) or up-regulated (B) pathways in T-ALL primary cells treated with ziftomenib.